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AN AUDIT OF PNEUMOCYSTIS JIROVECI PNEUMONIA IN
RHEUMATOLOGY PATIENTS IN THE CANTERBURY REGION
OVER A 5 YEAR PERIOD
Meuli KA,1 Chapman PT,1,2 O’Donnell JL1 and Stamp LK1,2
1Department of Rheumatology, Immunology and Allergy,
Christchurch Hospital, 2Department of Medicine, University of
Otago, New Zealand
Aim: To determine the prevalence of pneumocystis jiroveci pneu-
monia (PJP) in rheumatology patients prescribed methotrexate or
cyclophosphamide by the Christchurch Hospital rheumatology
service over a 5 year period.
Methods: The Canterbury Health Laboratory database was
searched for rheumatology patients testing positive for PJP from
31 December 2000–31 December 2005. The rheumatology data-
base was then searched to identify patients receiving the same
immunosuppressant medication as those who developed PJP to
give us the 5 year period prevalence of PJP infection in this patient
group.
Results: 3 infected rheumatology patients in the Canterbury
region were confirmed. 2 of these patients were women, receiv-
ing oral methotrexate for rheumatoid arthritis. The third patient,
a man with Wegeners granulomatosis was receiving oral
cyclophosphamide. 1050 patients were prescribed methotrexate
over the same 5 year period and 53 were treated with cyclophos-
phamide. Data on demographics, duration of treatment, use of
PJP prophylaxis and lymphocyte counts were analysed.
Conclusions: The 5 year period prevalence of PJP in rheumatol-
ogy patients receiving immunosuppressant treatment with
methotrexate or cyclophosphamide was low, despite minimal use
of prophylactic treatment. Our results indicate that routine PJP
prophylaxis is not required in this patient group.
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MACROPHAGE MIGRATION INHIBITORY FACTOR MODULATES
GLUCOCORTICOID SENSITIVITY VIA EFFECTS ON MAP KINASE
PHOSPHATASE-1
Morand EF, Yang YH, Mansell A, Santos LL, Leech M and 
Aeberli D
Monash Institute for Medical Research, Melbourne, Australia
Aim: The requirement for high-dose glucocorticoids (GC) is a
major clinical problem in inflammatory diseases. Factors regulat-
ing GC-resistance, or impaired GC-sensitivity, are poorly under-
stood. Expression of the pro-inflammatory cytokine macrophage
migration inhibitory factor (MIF) is induced by GC, and MIF
opposes the actions of GC. We hypothesised that MIF regulates
sensitivity to GC.
Methods: Macrophages derived from MIF−/− and wt mice were
treated with dexamethasone (DEX) and LPS, and TNF measured
by ELISA. MAP kinase phosphatase-1 (MKP-1), I-kappaB and
phospho-MAP kinases were measured by western blotting. NF-
kappaB activation was also measured by EMSA and a luciferase
reporter assay. Protein results were confirmed using real time
PCR.
Results: DEX significantly and dose-dependently inhibited LPS-
induced TNF in both wt and MIF −/− macrophages, but MIF −/−
macrophages demonstrated a 3-fold increase in sensitivity to DEX
(P < 0.0001). No differences in any parameter of NF-kappaB acti-
vation in response to LPS or DEX were detected between wt and
MIF −/− cells. In contrast, DEX induced a significant and selective
reduction in phospho-p38 MAP kinase in MIF −/− cells which was
not observed in wt cells. This was accompanied by significant
increased sensitivity to DEX-induced expression of the endoge-
nous MAP kinase inhibitory protein MKP-1 in MIF −/− cells. DEX-
induced MKP-1 expression was inhibited by exogenous
recombinant MIF.
Conclusions: We have demonstrated that endogenous MIF regu-
lates sensitivity to GC and report a novel mechanism for this
observation. Identification of factors regulating GC-sensitivity
may allow the development of specific steroid-sparing therapies.
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INVESTIGATING THE PHARMACOKINETIC AND PHARMA-
CODYNAMIC INTERACTION BETWEEN ALLOPURINOL AND
PROBENECID IN HEALTHY SUBJECTS
Williams KM,1 Stocker SL,1 McLachlan AJ,2 Graham GG1 and 
Day RO1
1University of NSW, St Vincent’s Hospital, and 2University of
Sydney, Australia
Aims: Allopurinol is co-administered with probenecid in patients
with gout refractory to monotherapy. However, surprisingly little is
known about the benefits of this combination. Therefore, the aims
were to investigate the pharmacokinetic and pharmacodynamic
interaction between allopurinol and probenecid in healthy subjects.
Methods: Healthy subjects (n = 12) ingested allopurinol (150mg
bd, 7d), probenecid (500mg bd, 7d) and the combination (1-week
washout between treatments). Urine and plasma samples were
collected at baseline for measurement of urate concentrations. On
the 8th day, after fasting overnight, subjects received the respec-
tive morning dose of drug(s). Blood and urine samples were 
collected over 12h for measurement of oxypurinol and urate 
concentrations, respectively.
Results: Plasma urate decreased from baseline (mean ± sd, 0.30 ±
0.05mM) when both allopurinol (0.17 ± 0.06mM, p < 0.001) and
probenecid (0.15 ± 0.06mM; p < 0.001) were administered individ-
ually. Co-administration caused a further decrease in plasma urate
(to 0.09 ± 0.02mM). Despite the greater effect of the combination on
urate concentrations in plasma, co-administration of allopurinol
with probenecid substantially (45%) decreased the average steady-
state concentration of the active metabolite, oxypurinol (9.4 ±
2.4mg/L, allopurinol alone; combination, 5.0 ± 1.0mg/L, p < 0.001).
Conclusions: The combination of allopurinol and probenecid had
a greater effect on plasma urate than either drug alone, despite
plasma oxypurinol concentrations decreasing by almost half
when they were co-administered to healthy subjects. Studies in
patients with gout are warranted in order to better understand and
optimise therapy with this combination.
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HEALTH-RELATED QUALITY OF LIFE AND PSYCHOLOGICAL DIS-
TRESS DO NOT RETURN TO POPULATION NORMS 12 MONTHS
AFTER JOINT REPLACEMENT SURGERY (JRS)
Ackerman IN, Graves SE, Bennell KL and Osborne RH
University of Melbourne and Royal Melbourne Hospital, 
Melbourne, Australia
Aim: People entering a public hospital orthopaedic waiting list for
primary JRS had very poor Health-Related Quality of Life (HRQoL)
and high psychological distress, compared with the general pop-
ulation. The aim was to compare HRQoL and psychological 
distress 12 months after total hip or knee replacement with 
Australian population norms.
Methods: 90 patients who received JRS at the Royal Melbourne
Hospital were assessed at entry to the list (baseline) and 12
months post-operatively, using the Assessment of Quality of Life
(AQoL) Instrument and K10 Psychological Distress scale. Data
were compared with Australian population norms. Pre-operative
predictors of 12 month outcome were identified using linear
regression. Questionnaires: AQoL: −0.04 (poorest HRQoL) to 1.00
(full HRQoL); K10: 10 (lowest distress) to 50 (highest distress), K10
≥22 indicates high distress.
Results: Mean (SD) AQoL score increased from 0.40 (0.24) at
baseline to 0.57 (0.26) at 12 months, representing large clinically
important improvement. HRQoL (mean 0.57, SD 0.26) remained
lower than for the overall population (0.83, 0.20) and subgroups
aged 60–69 (0.79, 0.19) and 70–79 (0.75, 0.25). Although psycho-
logical distress improved after surgery, the prevalence of high dis-
tress was 3 times greater than for the population (RR 3.0, 95% CI
2.2 to 4.1). Wellbeing at entry to the list was the strongest 
predictor of post-operative HRQoL and psychological distress.
Conclusions: While JRS produced large gains in HRQoL, this did
not return to population norms at 12 months and high psycho-
logical distress remained much more prevalent. Joint replace-
ment surgery is effective, but does not restore full wellbeing.
